Hopewell Therapeutics raised $2.5 million to develop tissue-targeted lipid nanoparticles (ttLNPs) for delivering genomic medicines. Their technology aims to precisely target cells throughout the body, enabling potential treatments for rare genetic diseases, lung disorders, oncology, and neurological conditions.
